Recombinant Full Length Human CAPN2 Protein, C-Flag-tagged

• Cat.No.: CAPN2-115HFL
• Product Overview: Recombinant Full Length Human CAPN2 Protein, fused to Flag-tag at C-terminus, was expressed in Mammalian cells.

Specification

• Description: The calpains, calcium-activated neutral proteases, are nonlysosomal, intracellular cysteine proteases. The mammalian calpains include ubiquitous, stomach-specific, and muscle-specific proteins. The ubiquitous enzymes consist of heterodimers with distinct large, catalytic subunits associated with a common small, regulatory subunit. This gene encodes the large subunit of the ubiquitous enzyme, calpain 2. Multiple heterogeneous transcriptional start sites in the 5' UTR have been reported. Two transcript variants encoding different isoforms have been found for this gene.
• Source: Mammalian cells
• Species: Human
• Tag: Flag
• Form: 25 mM Tris HCl, pH 7.3, 100 mM glycine, 10% glycerol.
• Molecular Mass: 79.8 kDa
• AA Sequence: MAGIAAKLAKDREAAEGLGSHERAI KYLNQDYEALRNECLEAGTLFQDPS FPAIPSALGFKELGPYSSKT RGIEWKRPTEICADPQFIIGGATRT DICQGALGDCWLLAAIASLTLNEEI LARVVPLNQSFQENYAGIFH FQFWQYGEWVEVVVDDRLPTKDGEL LFVHSAEGSEFWSALLEKAYAKING CYEALSGGATTEGFEDFTGG IAEWYELKKPPPNLFKIIQKALQKG SLLGCSIDITSAADSEAITFQKLVK GHAYSVTGAEEVESNGSLQK LIRIRNPWGEVEWTGRWNDNCPSWN TIDPEERERLTRRHEDGEFWMSFSD FLRHYSRLEICNLTPDTLTS DTYKKWKLTKMDGNWRRGSTAGGCR NYPNTFWMNPQYLIKLEEEDEDEED GESGCTFLVGLIQKHRRRQR KMGEDMHTIGFGIYEVPEELSGQTN IHLSKNFFLTNRARERSDTFINLRE VLNRFKLPPGEYILVPSTFE PNKDGDFCIRVFSEKKADYQAVDDE IEANLEEFDISEDDIDDGFRRLFAQ LAGEDAEISAFELQTILRRV LAKRQDIKSDGFSIETCKIMVDMLD SDGSGKLGLKEFYILWTKIQKYQKI YREIDVDRSGTMNSYEMRKA LEEAGFKMPCQLHQVIVARFADDQL IIDFDNFVRCLVRLETLFKIFKQLD PENTGTIELDLISWLCFSVLSGPTR TRPLEQKLISEEDLAANDILDYKDD DDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade.
• Concentration: >50 ug/mL as determined by microplate BCA method.
• Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps.
• Protein Families: Druggable Genome, Protease
• Protein Pathways: Alzheimer's disease, Apoptosis, Focal adhesion

Gene Information

• Gene Name: CAPN2 calpain 2 [ Homo sapiens (human) ]
• Official Symbol: CAPN2
• Synonyms: CANP2; mCANP; CANPL2; CANPml
• Gene ID: 824
• mRNA Refseq: NM_001748.5
• Protein Refseq: NP_001739.3
• MIM: 114230
• UniProt ID: P17655

Reviews

03/05/2020

The CAPN2 protein has been extensively studied and validated in various experimental applications.

08/03/2019

Their team of technical experts possess deep knowledge and expertise regarding the protein, ensuring that researchers receive accurate and timely assistance.

10/01/2017

In addition to its advantages in trials, the manufacturer of the CAPN2 protein offers exceptional support to researchers.

Q&As

How is CAPN2 protein expression regulated in normal physiological conditions?

CAPN2 activity is tightly regulated by intracellular calcium levels and various other factors to maintain cellular homeostasis.

How does CAPN2 protein interact with other molecules or proteins in disease contexts?

CAPN2 interacts with various cellular proteins, contributing to processes like protein degradation, cytoskeletal remodeling, and cell signaling, influencing disease pathways.

Can CAPN2 protein serve as a potential therapeutic target?

Research suggests that modulating CAPN2 activity could be a potential therapeutic strategy for managing diseases associated with its dysregulation.

Are there any drugs or compounds known to modulate CAPN2 activity?

Some compounds and inhibitors targeting CAPN2 have been developed in preclinical studies, showing promise in controlling its activity for therapeutic purposes.

Can CAPN2 protein levels serve as a biomarker for certain diseases?

In some cases, altered levels of CAPN2 have been observed in disease states, suggesting its potential as a biomarker, but further validation is needed.